GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 36 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,022 | -30.0% | 15,980 | -7.4% | 0.00% | – |
| Q2 2023 | $65,738 | +102.3% | 17,254 | -1.2% | 0.00% | – |
| Q1 2023 | $32,492 | -31.0% | 17,469 | -14.6% | 0.00% | – |
| Q4 2022 | $47,060 | -37.3% | 20,461 | -12.3% | 0.00% | – |
| Q3 2022 | $75,000 | -44.0% | 23,319 | -4.0% | 0.00% | – |
| Q2 2022 | $134,000 | -44.9% | 24,278 | -76.7% | 0.00% | – |
| Q1 2022 | $243,000 | +125.0% | 104,419 | +482.7% | 0.00% | – |
| Q4 2021 | $108,000 | – | 17,919 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,962,399 | $4,513,518 | 0.88% |
| Cheyne Capital Management (UK) LLP | 98,120 | $225,676 | 0.39% |
| Orbimed Advisors | 7,884,870 | $18,135,201 | 0.35% |
| Vivo Capital, LLC | 961,358 | $2,211 | 0.26% |
| EcoR1 Capital, LLC | 3,343,202 | $7,689,365 | 0.23% |
| Capital International, Inc./CA/ | 2,942,807 | $6,768,456 | 0.15% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $22,774,462 | 0.13% |
| Capital International Sarl | 297,193 | $683,544 | 0.05% |
| FEDERATED HERMES, INC. | 1,298,578 | $2,986,729 | 0.01% |
| Schonfeld Strategic Advisors LLC | 374,841 | $862,134 | 0.01% |